Skip to main content
OpenTrials
Completed

NCT Number: NCT00095446

NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

This trial is conducted in the United States of America (USA). The aim of this trial is to assess control of blood sugar, safety, and patient acceptance of insulin aspart compared to insulin lispro, both in insulin pumps, in standard clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Novo Nordisk Investigational Site

Princeton, New Jersey, 08540, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • People with Type I or Type II Diabetes
  • 18 Years or Older.

Treatment and study plan

insulin aspart

Drug

Primary outcomes

  1. Treatment satisfaction with insulin pump therapy

Secondary outcomes

  1. body weight

  2. Insulin dose

  3. Overall glycemic control

  4. number and types of infusion sets used.

  5. infusion set in-use times

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

An Open-Label, Multi Center, Clinical Trial: External Continuous Subcutaneous Infusion of Insulin Using Insulin Aspart (NovoLog®) in Subjects With Type 1 and Insulin Requiring Type 2 Diabetes

Important dates

Study start
2004
Primary completion
2005
Study completion
2005
First posted
Nov 5, 2004
Registry last updated
Jan 4, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.